Mayo Clinic, headquartered in Rochester, Minnesota, has unveiled collaborations with two AI-driven companies, Cerebras and Techcyte, to enhance their personalised medicine capabilities. Cerebras, a Silicon Valley startup, has been chosen as Mayo Clinic's first generative AI collaborator to develop large-scale, domain-specific AI capabilities for personalised diagnosis and treatment plans. The partnership involves a "multimillion-dollar" agreement lasting several years, where Cerebras will provide Mayo Clinic with hardware and software development services. The collaboration aims to leverage AI in summarising medical records, identifying patterns in medical images, and analysing genome data to improve patient outcomes.
Mayo Clinic Platform has also expanded its partnership with Techcyte, an AI-based digital pathology company. Together, they intend to create a digital pathology platform using open, end-to-end, AI-driven solutions to enhance the accuracy of medical treatment. Techcyte, which already collaborates with Mayo Clinic in digitising diagnostic testing and lab medicine, will now work on developing a software-as-a-service-based digital pathology platform. This platform aims to integrate various stakeholders in healthcare, including pathologists, LIS vendors, whole slide scanner manufacturers, storage, AI providers, biopharma, and labs, contributing to a comprehensive and global approach to digital pathology.
Mayo Clinic's collaborations with Cerebras and Techcyte represent strategic efforts to integrate artificial intelligence into personalised medicine. These partnerships aim to leverage advanced AI capabilities for more accurate diagnosis and treatment plans while also facilitating the development of a digital pathology platform that involves multiple healthcare stakeholders.
Click here to read the original news story.